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RESEARCH ARTICLE

Increased receptor-mediated gene delivery to the liver
by protamine-enhanced-asialofetuin-lipoplexes
MA Arangoa1, N Düzgünes¸2 and C Tros de Ilarduya1
1
2

Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain; and
Department of Microbiology, School of Dentistry, University of the Pacific, San Francisco, CA, USA

A novel lipidic vector composed of DOTAP/Chol liposomes,
asialofetuin (AF), protamine sulfate and DNA has been
developed. The resulting protamine-AF-lipoplexes improved
significantly the levels of gene expression in cultured cells
and in the liver upon i.v. administration. Lipoplexes containing the optimal amount of AF (1 mg/mg DNA) showed a 16fold higher transfection activity in HepG2 cells than nontargeted (plain) complexes. The uptake by cells having
asialoglycoprotein receptors (ASGPr) on their plasma membrane was decreased by the addition of free AF, indicating
that AF-lipoplexes were taken up specifically by cells via
ASGPr-mediated endocytosis. Results from transfections
performed in cells defective in ASGPr, ie HeLa cells,
confirmed this mechanism. By addition of the condensing
peptide, protamine sulfate, smaller complexes were obtained, which enhanced even more the uptake of AFcomplexes in HepG2 cells and in the liver. The optimal

amount of protamine was 0.4 mg/mg DNA, and gene expression was about 5-fold over that obtained with AF-lipoplexes in
the absence of the peptide, and 75-fold higher than that with
plain conventional lipoplexes. Protamine-AF-lipoplexes increased by a factor of 12 luciferase gene expression in the
liver of mice administered systemically via the tail vein,
compared to plain complexes. In summary, our findings
extend the scope of previous studies where AF-lipoplexes
were used to introduce DNA into hepatocytes. The combination of targeting and protamine condensation obviated the
need for partial hepatectomy, commonly required to obtain
efficient gene delivery in this organ. Since protamine sulfate
has been proven to be non-toxic in humans, the novel liverspecific vector described here may be useful for the delivery
of clinically important genes to this organ.
Gene Therapy (2003) 10, 5–14. doi:10.1038/sj.gt.3301840
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Introduction
The liver possesses a variety of characteristics that make
this organ very attractive for gene therapy. The proportion of administered macromolecules internalized by
hepatocytes depends on their particle size and biochemical characteristics. Only relatively small molecules can
pass the fenestrae of sinusoidal endothelial cells in the
liver, since their diameter is about 100 nm. On the other
hand, the basic mechanism underlying targeted delivery
is ligand-receptor interactions. Specific targeting to the
liver has been achieved by using ligands that bind the
asialoglycoprotein receptor (ASGPr), which is uniquely
present on hepatocytes in large numbers with highaffinity binding.1 Asialofetuin (AF), a glycoprotein
having triantennary galactose terminal sugar chains, is
known as an excellent ligand molecule selectively
recognized by ASGPr.2
For liver gene delivery, both virus-mediated3–5 and
non-viral systems have been considered. Although some
of the virus-mediated gene transfer systems have been
found to be quite effective, their usefulness is limited,
Correspondence: Dr C Tros de Ilarduya, Departamento de Farmacia y
Tecnologı́a Farmacéutica, C/ Irunlarrea s/n, Facultad de Farmacia,
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given that they induce an immune response, leading to
the rapid rejection of transduced cells. To overcome this
problem, artificial, non-viral gene delivery systems are
being developed, including small liposomes,6–8 particle
bombardment,9 gene gun,10 electroporation,11 chylomicron remnants12 and cationic polymers.13 Successful
transfer and expression in the liver can also be achieved
by systemic administration of naked plasmid using a
hydrodynamic-based procedure.14,15 One major concern
for this technique is that it requires an injection volume
of 8% of the body weight, which may alter the
physiological conditions of the liver. Localized hepatic
gene expression has also been achieved using direct
hepatic DNA injection.16
The feasibility of targeted gene delivery to hepatocytes
through the ASGPr has been amply demonstrated by the
work of Wu et al.17–22 In this system, DNA molecules are
complexed with a stretch of polylysine (PLL), which is
coupled to the asialoglycoprotein moiety. PLL residues
are intended to interact with DNA and the asialoglycoprotein behaves as a homing device to target hepatocytes. Although effective, these complexes have some
limitations. The ratio of asialoglycoprotein to PLL is
somewhat unpredictable, resulting in heterogeneous and
unstable complexes, with different DNA-binding capacities. Another problem, apart from the low efficiency, is
that the strong affinity of PLL for cells23 limits the
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targeting ability of these conjugates despite the inclusion
of cell-binding ligands. Furthermore, the activation of
components of the complement system by PLL reduces
the half-life of ligand-PLL/DNA complexes in vivo.
Other authors have also designed different systems
targeted to the ASGPr24,25 in the presence of PLL.
Lipoplexes have become a widely used non-viral gene
delivery system and are formed when cationic liposomes
are mixed with plasmid DNA. Various liposomal
formulations containing modified galactolipids have
been optimized for maximum liver uptake.26,27 Hara et
al28–30 reported that AF-labeled liposomes encapsulating
plasmid DNA is effective in gene expression after
intraportal injection with a preload of EDTA. On the
other hand, Zanta et al31 reported ASGPr-mediated in
vitro gene delivery by a 5% galactose-bearing-PEIpolymer. The major limitation of most of these methods
is that they require a local administration or surgical
procedures. The resulting level is relatively low and
restricted to the injection site, and sustained expression
often implies previous partial hepatectomy.19,21,32,33
Protamine sulfate, as a component of non-viral vectors,
may promote the delivery of DNA from the cytoplasm
into the nucleus. It has been proposed that this peptide
increases lipid-mediated gene transfection by condensing DNA into a compact structure, which promotes
cellular entry and stability of DNA.34,35 The use of this
polycation could also improve the in vivo activity of
lipoplexes36,37 and has the additional advantage of being
non-toxic in humans. In this study we examined whether
a liver-targeted, stable gene transfer system could be
constructed by combining the condensing effect of
protamine and the targeting capability of AF.

Results
Optimization of asialofetuin-lipoplexes
In order to obtain efficient complexes for gene delivery in
vitro and in vivo, lipoplexes were prepared in the
presence of different amounts of AF. The particle size,
zeta potential and the protection of the plasmid inside
the complexes from attack by degrading enzymes in
vitro, were determined as a function of the amount of the
ligand. Figure 1 shows the values of the particle size and
the zeta potential of AF-liposomes and lipoplexes at 4/1
(+/) charge ratio containing plasmid DNA (1 mg of
pCMVLuc) in the absence or presence of increasing
amounts of AF. It is important to consider that the size
and the overall charge of starting liposomes was 120 nm
and 47 mV, respectively. By increasing the amount of
asialofetuin to 1 mg (per microgram of DNA) the particle
size of AF-liposomes increased slightly to approximately
130 nm. The same behavior was observed for AFlipoplexes, which reached a size of 302 nm. The zeta
potential of AF-liposomes and lipoplexes showed clearly
positive values by using amounts of asialofetuin lower
than 1 mg. AF-complexes aggregated at 4.5 and 9 mg AF/
mg DNA, which corresponds to a value of the zeta
potential close to the electroneutrality. AF-liposomes in
the presence of 4.5 mg AF also aggregated, and exhibit a
zeta potential close to zero. Amounts of the ligand above
18 mg lead to AF-liposomes and lipoplexes of 130 nm
with a markedly negative surface charge.
Gene Therapy

Figure 1 Optimization of AF-lipoplexes. Particle size (open symbols) and
zeta potential (closed symbols) of DOTAP/Chol liposomes (circles) and
lipoplexes (squares) in the absence or presence of different amounts of
asialofetuin. Each value represents the mean 7 s.d. (n¼3).

To establish whether the plasmid inside the complexes
is protected from degradation by DNases, an in vitro
DNase I protection assay was performed. Lipoplexes
were prepared at 4/1 (+/) charge ratio and contained
2.5 mg of pCMVLuc. Gel electrophoresis data indicated
that naked DNA was degraded quickly (Figure 2, lane 2),
while the plasmid inside AF-lipoplexes containing an
amount of AF below 4.5 mg was protected completely

Figure 2 Protection assay. Stability to degradation by DNase I of free
DNA or DNA formulated in AF-lipoplexes with different amounts of the
ligand. Untreated DNA (lane 1), DNA treated with DNase: naked plasmid
(lane 2), DNA inside lipoplexes prepared with zero (lane 3), 0.1 (lane 4), 1
(lane 5), 4.5 (lane 6), 9 (lane 7) and 18 (lane 8) mg AF/mg DNA.
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(Figure 2, lanes 3–6). Quantification of the intensity of the
bands in the gel, also showed some DNase degradation
(50% compared to naked DNA) in complexes with 9 mg
of AF (Figure 2, lane 7) and practically total degradation
(70%) when lipoplexes were prepared with 18 mg of the
ligand (Figure 2, lane 8).

Effect of asialofetuin on lipofection activity in HepG2
cells
Figure 3 shows the luciferase gene expression of
complexes formulated at 4/1 (+/) charge ratio and
1 mg of pCMVLuc, with different amounts of AF.
Complexes containing the ligand in the range from 0.01
to 9 mg AF/mg DNA gave always higher values of gene
expression compared to plain lipoplexes (without
ligand), with the optimal amount being 1 mg. This
complex showed a 16-fold higher transfection activity
than non-targeted lipoplexes. Complexes prepared with
amounts of the ligand above 9 mg decreased gene
expression dramatically. In fact, levels of luciferase
expression obtained with AF-lipoplexes containing
36 mg AF/mg DNA were 4-fold lower than that obtained
with plain complexes. No gene expression was detected
with the naked plasmid.
Specificity of targeting to the asialofetuin receptor
To elucidate whether the uptake of AF-lipoplexes,
prepared at 4/1(+/) charge ratio and with 1 mg of
plasmid DNA, is mediated via interaction with the AF
receptor, a competitive inhibition experiment was performed in the presence of an excess of the free ligand. In
addition, HeLa cells, which are deficient in ASGPr, were
used in this experiment. Figure 4 shows that the
treatment of HepG2 cells with 1 mg of free AF previous

Figure 3 In vitro transfection activity by AF-lipoplexes. Transfection of
HepG2 cells by plain and AF-lipoplexes as a function of the amount of the
ligand. The data represent the mean 7 s.d. of three wells and are
representative of three independent experiments.

Figure 4 Competition assay. Gene expression by plain and AF-lipoplexes
in HepG2 cells in the absence (&) or presence of an excess of free AF ( )
and in HeLa cells (&). The data represent the mean 7 s.d. of three wells
and are representative of three independent experiments.

to the addition of complexes significantly inhibited gene
expression of AF-lipoplexes but not that of plain
complexes. Lipoplexes containing 1, 4.5 and 9 mg of AF
showed a 3-, 3- and 9-fold decrease in the levels of gene
expression, respectively. On the other hand, the same
lipoplexes presented a 23-, 156- and 194-fold decrease,
respectively, when added on HeLa cells, however, no
differences were observed with plain complexes. These
results support the hypothesis that AF-lipoplexes are
recognized by the ASGPr on HepG2 cells.

Effect of protamine sulfate on gene expression
mediated by AF-lipoplexes
AF-lipoplexes, with 1 mg of DNA at 4/1 (+/) charge
ratio, in the absence or presence of different amounts of
protamine sulfate, were incubated with HepG2 in the
presence of 60% FBS. Figure 5 shows the gene expression
as a function of the amount of the condensing peptide.
Independent of how much protamine was used in the
formulation of complexes, the presence of AF resulted
always in higher values of gene expression compared to
plain lipoplexes. The optimal amount of protamine
resulted to be 0.4 mg/mg DNA and gene expression was
calculated to be about 5-fold over the value obtained
with AF-lipoplexes in the absence of the peptide. This
value was 30 times higher than the one obtained by plain
lipoplexes with the same amount of protamine. Peptide
amounts above 0.4 mg decreased the gene expression
dramatically. Table 1 shows the particle size of plain and
AF-lipoplexes at 4/1 (+/) charge ratio, containing 1 mg
of the ligand, 1 mg of pCMVLuc and different amounts of
protamine sulfate per microgram of DNA. By increasing
Gene Therapy
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be 184 nm and 26 mV, respectively. As shown in Figure 7,
these complexes improved significantly luciferase expression, which was calculated to be about 12- and 3-fold
higher than plain and AF-lipoplexes, respectively. No
transfection activity was detected by injecting the naked
DNA. In vivo competition experiments were performed
by previous pretreatment of mice with free asialofetuin
(25 mg/kg), leading to a clear inhibition of the gene
expression in the liver by AF-lipoplexes. This fact
corroborates that the in vivo uptake is also mediated by
the ASGPr.
The efficiency of transfection mediated by protamineAF-lipoplexes was also evaluated by monitoring the
expression of green fluorescent protein (GFP) intensity
and comparing this efficiency with that of transfection
mediated by plain lipoplexes and naked DNA. For this
purpose, frozen liver sections from mice injected with
PBS (controls), DNA alone, plain and protamine-AFlipoplexes were examined under a fluorescence microscope. The reporter plasmid pCMV-GFP gave similar
results to the luciferase activity, showing that fluorescence by protamine-AF-lipoplexes is superior to that of
plain lipoplexes. No fluorescent cells were observed in
control animals or in mice administered with GFP
plasmid alone (Figure 8). In the same figure is also
shown the absence of liver damage, given that no
obvious histological changes were seen in liver sections
of animals injected with plain and protamine-AF-complexes compared to control mice. The hepatocytes were
identified by their characteristic morphology.

Figure 5 In vitro gene expression by protamine-AF-lipoplexes. Transfection activity of plain and AF-lipoplexes containing 1 mg AF/mg DNA as a
function of the amount of protamine sulfate. The data represent the mean
7 s.d. of three wells and are representative of three independent
experiments.

the amount of the peptide to 0.6–0.8 mg the smallest size
was obtained. Addition of higher amounts of protamine
did not lead to smaller complexes.

Discussion
The existence of ASGPr in hepatocytes facilitates the
feasibility of lipoplexes-directed therapy to the liver. The
rate and extent of liposomal uptake by this organ is
highly variable and dependent on the size, charge,
composition, rigidity and other physicochemical properties of the particles. It is already known that delivery to
parenchymal cells in vivo is favored by small liposomes.6
For most vectors, high efficiency of transfection correlates with a large excess of cationic charges,38–40 however,
this large excess in vivo facilitates non-specific interactions with many undesired elements such as extracellular matrix and negatively charged serum components.
Taking this into account, the first aim of this work was to
optimize the size and the zeta potential of AF-lipoplexes
for maximum uptake by the liver after systemic administration.
As shown in Figure 1, AF amounts below 1 mg lead to
AF-lipoplexes of approximately 300 nm with a positive
value of the zeta potential, showing that addition of the

Cell viability assay
Cell viability following transfection was assessed to
evaluate whether plain and AF-lipoplexes (containing
1 mg AF/mg DNA), formulated with different amounts of
protamine, were toxic to the cells. The Alamar blue assay
showed a viability higher than 95% in all transfected
wells (Figure 6). The relative cytotoxicity of lipoplexes
was also assessed by the total amount of extractable
cellular proteins in the cell lysate per well, and confirmed
the results with the Alamar blue assay.
In vivo studies
In order to verify whether our complexes, prepared as
described in ‘Materials and methods’ could be used for
in vivo gene delivery, we evaluated the efficacy of
protamine-AF-lipoplexes injected systemically into mice.
The size and zeta potential of these complexes resulted to

Table 1 Size of protamine-AF-lipoplexes. Particle size of plain and AF-lipoplexes as a function of the amount of protamine. Results are
expressed in nm as the mean 7 S.D. of three experiments
Protamine sulfate (mg)
0

Plain lipoplexes
AF-lipoplexes

Gene Therapy

0.2

0.4

0.6

0.8

1

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

242
302

6
5

206
252

7
7

155
181

5
9

120
165

22
4

125
149

45
3

136
155

81
3
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Figure 6 Cell viability. Effect of plain and AF-lipoplexes on the viability of
HepG2 cells. The data represent the mean 7 s.d. of three wells and are
representative of three independent experiments.

ligand increases only slightly the particle size of plain
complexes and at the same time results in a decrease of
the surface charge. This effect is most likely due to the
negatively charged amino acids of the protein interacting

Figure 7 In vivo transfection activity. In vivo transfection activity of
plain, AF- and protamine-AF-lipoplexes. Complexes in the presence of the
polycation were prepared with 0.4 mg of protamine as described in
Materials and methods.

with the cationic liposomes. As it was expected, amounts
of the ligand between 4.5 and 9 mg, leading to a zeta
potential close to the electroneutrality, produced aggregates. Amounts of AF above 18 mg lead to complexes
with a negative surface charge and particle size even
smaller than plain complexes, possibly due to a lack of
interaction of DNA with the cationic lipid as a
consequence of the presence of a high amount of AF.
In order to avoid in vivo degradation by DNases, we
wanted to know if the plasmid is protected inside our
AF-lipoplexes. When the DNA itself was treated with
DNase I, under physiological conditions, complete
degradation occurred (see Figure 2, lane 2). Complete
protection of DNA inside the complexes was observed
when amounts of AF between 0.01 and 4.5 mg were used
(Figure 2, lanes 3–6). In these complexes, the interaction
of DNA with the lipid is strong enough to achieve
protection. When the amount of the ligand was 9 mg or
higher, some degradation of the plasmid occurred as a
result of the competition of AF with DNA for interaction
with the lipid (Figure 2, lanes 7 and 8). In this case, there
is more free DNA, which is not complexed, and therefore
exposed to DNase.
The association of AF with DOTAP/Chol/DNA
complexes increased luciferase expression compared to
plain lipoplexes when amounts of AF between 0.01 and
9 mg were used (Figure 3). The greatest enhancement was
obtained by complexes containing 1 mg of AF (16-fold).
These lipoplexes have a relatively small particle size,
which is in accordance with the results obtained by
Machy et al,41 who observed that small particles may be
more readily endocytosed by the cells, resulting in
increased levels of transgene expression. Another possible explanation for this enhancement is that non-specific
interactions of plain lipoplexes with negatively charged
macromolecules in serum most likely prevent their
binding to the cells, while AF-lipoplexes can interact
with cell surface receptors. DOTAP/Chol liposomes bind
AF through the negatively charged groups present in the
ligand at physiological pH, and the resulting structure
forms a complex with DNA through a charge–charge
interaction. Association of AF also appears to facilitate
the internalization of the complex, due to the ability of
the ligand to stimulate endocytosis.42 It is also worth
noting that, although other authors have reported gene
expression in HepG2 cells by AF-lipoplexes,29 the
enhancement achieved over plain complexes was much
lower (1.5-fold increase) than the one obtained with our
formulations. Moreover, all our in vitro experiments were
performed in the presence of 60% FBS, as in our previous
work.43,44 When the amount of AF was above 9 mg,
transfection activity by AF-lipoplexes was lower than
plain complexes, in spite of the presence of the ligand.
The competitive inhibition of transfection observed by
AF-lipoplexes in HepG2 cells in the presence of an excess
of free AF (Figure 4) supports the hypothesis that these
complexes are recognized by AF receptors on the cells
surface, which in turn facilitate receptor-mediated
endocytosis. Transfection was not inhibited completely,
despite the 1000-fold excess of free AF. This may be the
result of the higher avidity of the interaction of multiple
AF molecules on lipoplexes with their receptors. It may
also be caused in part by the charge interactions between
positive lipoplexes and the negative surface charge of
cells. Gene delivery and expression by plain lipoplexes

9
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Figure 8 Histological analysis. Histologic evaluation of GFP gene expression in hepatocytes after tail vein injection of PBS and naked DNA (a,b), plain
(c,d) and protamine-AF-lipoplexes (e,f). Cells under phase contrast microscopy (a,c,e) and under fluorescence microscopy (b,d,f). A representative overview
is shown.

did not show changes in the presence of such excess of
the ligand. On the other hand, transfection activity of AFcomplexes in HeLa cells (defective in ASGPr) also
decreased, compared to that obtained in HepG2 cells,
remaining in all cases lower than that of plain lipoplexes,
which can be bound to the cells by non-specific
interactions. On the other hand, it should be noted that
Gene Therapy

an increased charge ratio in the complexes does not
change the inhibitory effect of an excess of AF, not
altering the ASGPr-mediated uptake. These observations
lend support to the role of AF receptors in the
mechanism of transfection by AF-lipoplexes. In vivo
competition experiments also corroborated this mechanism.
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The next step we considered in this study was to precondense the DNA with protamine sulfate before the
addition of the ligand, in order to have smaller
complexes for maximum uptake by the liver after
intravenous administration. Figure 5 shows a dosedependent gene expression by protamine induced in
plain and AF-lipoplexes. Maximum level of transfection
was obtained at protamine concentration of 0.4 mg per
microgram of DNA. Under these conditions, the diameter of the AF-lipoplexes was reduced from 302 to
181 nm (see Table 1). Protamine maintains its ability to
condense the DNA without reducing further interactions
with the cationic lipids, acting synergistically with it to
enhace gene transfer. The use of this polycation could
improve the in vivo activity of lipoplexes by protecting
the DNA from the degradation by nucleases. Also, the
presence of nuclear localization signals in its amino acid
sequence can potentiate gene expression by increasing
the nuclear translocation of DNA.34 Continuous increase
in the amount of protamine was not associated with a
further increase in the levels of expression. On the
contrary, gene expression was even lower than AFcomplexes without the peptide. Probably, the neutralizing effect of an excess of protamine on DNA lead to
charge-neutralization, avoiding further interactions with
the cationic lipid and the ligand. The polycation itself in
combination with DNA had no significant effect on gene
expression. The differences in transfection activity
between these sets of complexes cannot be explained
by different toxicities of the formulations, since cell
viability was similar in all cases (Figure 6).
Although a number of gene delivery systems targeted
to the ASGPr have been designed, their in vivo efficiency
has been poorly documented. As shown in Figure 7,
protamine-AF-lipoplexes increase gene expression in the
liver compared to plain and AF-lipoplexes. The AF
molecule, in addition to acting as a ligand, neutralizes
part of the positive charge on the liposomes, possibly
leading to diminished interactions of the AF-lipoplexes
with polyanionic molecules in serum. The development
of a different structure in these AF-lipoplexes, together
with the assistance afforded by protamine in the nuclear
transport of plasmid and the reduction of the size, are
likely to be additional reasons why the transfection
activity is enhanced. AF-lipoplexes acquired resistance to
nuclease attack in vitro (see Figure 2), which might be
correlated with in vivo protection of DNA against
endogenous DNases. Moreover, in these lipoplexes the
addition of protamine has helped to reduce the need for
a large amount of cationic lipid. Consequently, no signs
of toxicity were evident when protamine-AF-lipoplexes
were injected into mice compared to plain complexes.
Results shown in Figure 8 corroborated this observation.
Intense green staining was evenly distributed throughout the liver, when mice were injected with protamineAF-lipoplexes compared to plain complexes. The extent
of staining is consistent with the luciferase levels,
positively staining cells being mainly hepatocytes. None
of the liver sections observed showed evidence of necrosis.
In summary, the novel protamine-AF-lipoplexes developed in this study, have improved transfection activity
both in vitro and in vivo. Although various methods have
been used for the preparation of polycation–ligand–DNA
complexes, covalent binding is usually needed, and
insoluble aggregates are formed unless the concentration

of the polycation or DNA is minimized. The complexes
in this study, however, were prepared by simple mixing
of the peptide and the ligand, without having problems
of aggregation. Although previous studies have shown
that the association of AF with lipoplexes enhances
transfection, this is the first demonstration of the efficacy
of the combination of the condensing action of protamine
and the targeting effect of the ligand in vivo. The
synthetic nature of this system provides the potential of
flexibility in terms of composition, and the capability of
inexpensive and large-scale production of the complexes.
Further improvement of this non-viral vector, such as
prolonged expression of the transgene, could bring us
into the range of a gene delivery system with clinical
benefit.
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Materials and methods
Materials
The cationic lipid 1,2-dioleoyl-3-(trimethylammonium)
propane (DOTAP) and cholesterol (Chol) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
AF Type I, N-(2-hydroxyethyl) piperazine-N0 -2-ethanesulfonic acid (HEPES) and protamine sulfate (derived
from salmon) were obtained from Sigma (Madrid,
Spain). Alamar Blue dye was purchased from Accumed
International Companies (Westlake, OH, USA), and
DNase I and ethidium bromide from GibcoBRL Life
Technologies (Barcelona, Spain). The plasmids,
pCMVLuc (VR-1216) and pCMV-GFP (Clontech, Palo
Alto, CA, USA), encoding luciferase and GFP, respectively, were used for carrying out the transfection
experiments. Plasmids were amplified in E. coli, isolated,
and purified using a QIAGEN Plasmid Giga Kit
(QIAGEN GmbH, Hilden, Germany). Purity was confirmed by 0.8% agarose gel electrophoresis followed by
ethidium bromide staining and the DNA concentration
was measured by UV absorption at 260 nm. The reagents
used in the histological analysis of GFP gene expression
were from Merck (Barcelona, Spain).
Cell culture
HepG2 (human hepatoblastoma) and HeLa (human
cervix carcinoma) cells were obtained from American
Type Culture Collection (Rockville, MD, USA). The cells
were maintained at 371C under 5% CO2 in Dulbecco’s
modified Eagle’s medium-high glucose (DMEM), supplemented with 10% (v/v) heat-inactivated fetal bovine
serum (FBS), penicillin (100 units/ml), streptomycin
(100 mg/ml) and L-glutamine (4 mM) (all from GibcoBRL
Life Technologies, Barcelona, Spain).
Preparation of lipoplexes
Firstly, DOTAP/Chol (1:0.9 molar ratio) liposomes were
prepared by drying a chloroform solution of the lipids by
rotary evaporation under reduced pressure. Then, the
film was hydrated with a 10 mM HEPES, 10% (w/v)
glucose buffer (pH 7.4), to give a final concentration of
10 mM DOTAP/9 mM Chol. The resulting multilamellar
vesicles were extruded 5 times through polycarbonate
membranes with 100 nm pore diameter using a Liposofast device (Avestin, Toronto, Canada), to obtain a
uniform size distribution and filter-sterilized (Millex
0.22 mm, Millipore, Bedford, MA, USA). Liposomes were
Gene Therapy
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stored at 41C under nitrogen and were used within 1
month after preparation.
Complexes for in vitro experiments were prepared at a
4/1 (+/) charge ratio by sequentially mixing 100 ml of a
solution of 10 mM HEPES, 10% (w/v) glucose buffer (pH
7.4) without (plain lipoplexes) or with a variable amount
of AF (AF-lipoplexes) and 22.8 nmol of the DOTAP/Chol
liposome suspension. After incubating for 15 min at
room temperature, 100 ml of water containing 1 mg of
pCMVLuc were added and gently mixed. Protamine-AFlipoplexes were prepared by pre-complexation of plasmid DNA with different amounts of protamine, followed
by the addition of cationic liposome-AF complexes.
Lipoplexes for in vivo experiments were prepared at a
5/1 (+/) charge ratio and contained 19 mM of total lipid
(DOTAP/Chol). Protamine-AF-lipoplexes were formulated with 0.5 mg of AF and 0.4 mg of protamine per
microgram of DNA. The final concentration of plasmid
in the complexes was 0.3 mg/ml. The lipid to DNA
charge ratio was calculated as the mole ratio of DOTAP
(one charge per molecule) to nucleotide residue (average
MW 330). The protocol used for the preparation of these
complexes implied also the pre-complexation of plasmid
DNA with protamine followed by the addition of preformed cationic liposomes-AF-complexes, prepared as
described above. The lipoplexes resulted to be of easy
preparation and very stable, without having problems of
aggregation, which was one of the main reasons to
choose this formulation for in vivo experiments.

Cell culture transfections
For transfection, 105 cells were seeded in 1 ml of medium
in 48-well culture plates (10 mm well diameter; Iwaki,
Japan) 24 h before addition of the complexes and used at
approximately 80% confluency. Cells were washed twice
with DMEM without antibiotics and then 0.3 ml of fetal
bovine serum and 0.2 ml of complexes were added
gently to each well. After a 4-h incubation in 60% FBS (at
371C in 5% CO2) the medium was replaced, and the cells
were further incubated for 48 h in medium containing
10% FBS.
In vitro transfection activity
After 48 h, cells were washed with phosphate buffered
saline (PBS) and lysed using 100 ml of reporter lysis
buffer (Promega) at room temperature for 10 min,
followed by two alternating freeze–thaw cycles. The cell
lysate was centrifuged for 2 min at 12 000 g to pellet
debris. Then, 20 ml of the supernatant was assayed for
total luciferase activity using the luciferase assay reagent
(Promega), according to the manufactureŕs protocol. A
luminometer (Sirius-2, Berthold Detection Systems,
Innogenetics, Diagnóstica y Terapéutica, S.A., Barcelona,
Spain) was used to measure luciferase activity. The
protein content of the lysates was measured by the DC
Protein Assay reagent (Bio-Rad, Hercules, CA, USA)
using bovine serum albumin as the standard. The data
were expressed as ng or pg of luciferase (based on a
standard curve for luciferase activity) per milligram of
protein.
DNase I protection assays
To evaluate the role of our complexes in the protection of
DNA, the naked plasmid and lipoplexes with different
amounts of AF were incubated in the presence of the
Gene Therapy

enzyme. DNase I (1 unit per mg of DNA) was added to
2.5 mg (DNA) of each sample and the mixtures were
incubated at 371C for 30 min. Two microliters of EDTA
(0.5 M) were immediately added to stop DNase degradation. Then, sodium dodecyl sulfate (SDS) was included to
a final concentration of 1% to release DNA from the
complexes. Finally, samples were analyzed by 0.8%
agarose gel electrophoresis and the integrity of the
plasmid in each formulation was compared with
untreated DNA as a control.

Cell viability assay
Cell viability was quantified by a modified Alamar Blue
Assay.45 Briefly, 1 ml of 10% (v/v) Alamar Blue dye in
DME-HG supplemented with 10% (v/v) FBS medium
was added to each well 48 h after transfection. After 2.5 h
of incubation at 371C, 200 ml of the supernatant was
assayed by measuring the absorbance at 570 and 600 nm.
Cell viability (as a percentage of control cells) was
calculated according to the formula (A570–A600) of treated
cells  100/(A570–A600) of control cells.
In vivo gene expression
Female Balb-c (8–10 weeks of age) mice were purchased
from Harlan Ibérica Laboratories (Barcelona, Spain). All
animals were studied in accordance with guidelines
established by Directive 86/609/EEC and with the
approval of the Committee on Animal Research at the
University of Navarra, Pamplona (033/00). Individual
mice in groups of eight were injected via the tail vein
with 60 mg of DNA formulated in plain, AF- or
protamine-AF-lipoplexes in a total volume of 200 ml 5%
w/v glucose. Twelve hours following iv injection, the
mice were killed with a sodium pentobarbital overdose.
The liver was collected and washed with cold saline
twice. The organs were homogenized with lysis buffer
(Promega) using a homogeneizer (Mini-BeadbeaterTM ,
BioSpec Products, Inc., Bartlesville, OK, USA) and
centrifuged at 12 000  g for 3 min at 41C. Finally, 20 ml
of the supernatant was analyzed for luciferase activity as
described previously. In the histological analysis, the
livers were dissected and immediately frozen. Sixmicrometer cryosections were made using a cryostat
(Microm, HM 505 E) and regular hematoxylin–eosin
staining was used. The sections were examined in a
microscope (Olympus CH-40, Japan) with fluorescence
source (Olympus U-RFLT50, Japan), equipped with a
digital camera (Olympus Camedia C-3030 zoom), at an
original magnification of  200.
Particle size and zeta potential measurements
The particle size of complexes was measured by dynamic
light scattering, and the overall charge by zeta potential
measurements, using a particle analyzer (Zetamaster,
Malvern Instruments, Spain). Samples of the prepared
complexes (2.5 ml) were measured 3 times for 60 s at
1000 Hz and an electric current of 3 mA with zero field
correction.
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